No Image found

Contact Information:
Carla D Kurkjian


Kurkjian, Carla D (HSC)

Department of:

College Of Medicine/Medicine Hematology/Oncology -Assistant Professor

Center of:

Peggy & Charles Stephenson Oklahoma Cancer Center -


University of Oklahoma, College of Medicine, Oklahoma City, Oklahoma   MD   2001
University of Oklahoma, College of Medicine, Oklahoma City, Oklahoma   Internal Medicine Resident   2004
University of Oklahoma, College of Medicine, Oklahoma City, Oklahoma   Hematology/Oncology Fellow   2007
National Cancer Institute   Advanced Developmental Therapeutics Fellow   2008

Professional Interest/Expertise/Specializations:
Gastrointestinal Cancers, Developmental Therapeutics


Research Projects:

Local PI: A Phase I, Open Label, Dose Escalation Study of Daily Oral Administration of INK128 in Combination with Paclitaxel, with/without Trastuzumab, in Subjects with Advanced Solid Malignancies.
Local PI: A Phase I PK/PD Study of the PI3 Kinase/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients with Advanced Solid Tumors
Local PI: An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 Administered Daily in Patients with Locally Advanced or Metastatic Solid Tumors.
Local PI: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Local PI: Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach

Selected Publications:

PARP Inhibitors: BRCA and Beyond
   Hopps S, Kurkjian C, Pant S
Submitted to Journal of Hematology Oncology Pharmacy August, 2011
Safety and Efficacy Results from the First-Time-in-Human Study of the Oral AKT Inhibitor GSK2141795
   Burris H, Siu L, Infante J, Wheler J, Kurkjian C
Oral Presentation Annual ASCO Meeting 2011
Risks and Benefits with Bevacizumab: Evidence and Clinical Implications.
   Kurkjian C, Kim E
Therapeutic Advances in Drug Safety. Submitted for publication May 2011
A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC)
   M. Gutierrez, S. Kummar, D. Allen, B. Turkbey, P. Choyke, J. J. Wright, C. Kurkjian, G. Giaccone, J. H. Doroshow, A. J. Murgo
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings. Vol 26, No 15S (May 20 Supplement), 2008: 19084
Advances in the Treatment of Metastatic Colorectal Cancer
   Kurkjian C, Kummar S
Am J Ther. 2009 Sep-Oct; 16(5): 412-420
DNA Methylation: Its Role in Cancer Development and Therapy
   Kurkjian C, Kummar S, Murgo AJ
Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235
of Recurrent Metastatic Colon Cancer in the Age of Modern Adjuvant Therapy
   Kurkjian C, Murgo AJ, Kummar S
Clin Colorectal Cancer. 2008 Sep;7(5):321-4.
Topics in clinical pharmacology: renal, gastrointestinal and pain management
   Kurkjian C, Kummar S, Stewart D
Dis Mon. 2010 Apr;56(4) 187-250